Subject(s)
Melanoma , Skin Neoplasms , Humans , Melanoma/drug therapy , Melanoma/genetics , Nivolumab/therapeutic use , Ipilimumab/therapeutic use , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , France , Antineoplastic Combined Chemotherapy ProtocolsABSTRACT
BACKGROUND: The recent publication of randomized trials investigating the efficacy of adjuvant therapy and completion lymph node dissection at microscopic stage III melanoma calls for a reappraisal of melanoma management from different angles: indications for sentinel lymph node biopsy, indications for completion lymph node dissection in microscopic-stage disease, and adjuvant therapies. Our objective was to evaluate current practices and to question French onco-dermatologists about any changes they envisaged in their practices in the light of recent publications. METHODS: We conducted a national survey among members of the Cutaneous Oncology Group of the French Society of Dermatology in October 2017. RESULTS: Forty French health centers were included, and 53 individual responses were collected. Sentinel lymph node biopsy for melanoma was performed at 75 % of the centers. Before the summer of 2017 and the publication of MSLT-II (proving the absence of any therapeutic benefits for complete lymph node dissection in microscopic stage III melanoma), when a positive sentinel lymph node was diagnosed, immediate completion lymph node dissection was performed at 90 % of the centers. After the publication of MSLT-II, 45 % of the respondents considered stopping this practice. The risk-benefit ratio prompted prescription of nivolumab and of combined dabrafenib+trametinib as adjuvant therapy by respectively 96 % and 79 % of respondents, while the corresponding rates for interferon and ipilimumab were only 21 % and 15 %. CONCLUSION: Early melanoma management stands on the verge of major changes thanks to the arrival of efficient adjuvant therapies and a decrease in immediate completion lymph node dissections for patients with microscopic stage III is also anticipated.
Subject(s)
Health Care Surveys , Lymph Node Excision/statistics & numerical data , Melanoma , Sentinel Lymph Node Biopsy/statistics & numerical data , Sentinel Lymph Node , Skin Neoplasms , Antineoplastic Agents/therapeutic use , Chemotherapy, Adjuvant , France , Humans , Imidazoles/therapeutic use , Interferons/therapeutic use , Ipilimumab/therapeutic use , Lymphatic Metastasis , Melanoma/drug therapy , Melanoma/pathology , Melanoma/secondary , Melanoma/surgery , Oximes/therapeutic use , Pyridones/therapeutic use , Pyrimidinones/therapeutic use , Randomized Controlled Trials as Topic , Risk Assessment , Sentinel Lymph Node/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Skin Neoplasms/surgeryABSTRACT
BACKGROUND: Transformed mycosis fungoides (TMF) large cells may express CD30 antigen, and because of this, the differential diagnosis between CD30-rich TMF and primary cutaneous anaplastic large-cell lymphoma (cALCL) may be difficult, and especially in distinguishing cALCL associated with MF vs. CD30-rich TMF. OBJECTIVES: To find clinical, histological and molecular diagnostic features useful for differential diagnosis between cALCL and CD30-rich TMF. To analyse and compare the prognostic value of clinical and pathological factors in these two diseases. MATERIAL AND METHODS: We conducted a retrospective study (1999-2012) of 32 patients with cALCL and 34 with CD30-rich TMF, seen in reference centres of the French Study Group of Cutaneous Lymphoma. Clinical, histological and molecular features were analysed and compared to determine their diagnostic and prognostic value. RESULTS: Comparison of the two groups showed that age Ë 60 years, ≥ 5 skin lesions, early progression, absence of spontaneous regression and trunk involvement were significantly associated with the diagnosis of TMF. Abnormal T-cell phenotype and perforin expression were significantly more frequent in cALCL (both P < 0·001). Overall survival (OS) at 5 years was 77·4% for cALCL and 20·7% for CD30-rich TMF. Stage T3, ≥ 5 skin lesions, lower limb involvement for cALCL and stage T4, extracutaneous involvement, B symptoms, high levels of lactate dehydrogenase for CD30-rich TMF were associated with poor OS and progression-free survival. DUSP22 gene rearrangement had no diagnostic or prognostic value. CONCLUSIONS: Clinical features and outcome are the most discriminative to differentiate the two entities. Even histological and molecular markers were not fully specific; abnormal vs. normal T-cell phenotype and perforin expression may constitute helpful tools.
Subject(s)
Biomarkers, Tumor/metabolism , Ki-1 Antigen/metabolism , Lymphoma, Primary Cutaneous Anaplastic Large Cell/diagnosis , Mycosis Fungoides/diagnosis , Skin Neoplasms/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Diagnosis, Differential , Female , France/epidemiology , Humans , Lymphoma, Primary Cutaneous Anaplastic Large Cell/mortality , Male , Middle Aged , Mycosis Fungoides/mortality , Perforin/metabolism , Phenotype , Retrospective Studies , Skin Neoplasms/mortality , T-Lymphocytes/pathology , Young AdultSubject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Skin Neoplasms/drug therapy , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized , Carcinoma, Squamous Cell/radiotherapy , Cetuximab , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Retrospective Studies , Skin Neoplasms/radiotherapyABSTRACT
BACKGROUND: The 308-nm excimer laser and 308-nm excimer lamp have both been shown to be effective in treating vitiligo but a direct comparison has never been performed. OBJECTIVES: To test the equivalence of these two devices for treating nonsegmental vitiligo. PATIENTS AND METHODS: A randomized monocentric study was undertaken. One lesion was treated with the 308-nm excimer laser and its counterpart with the 308-nm excimer lamp. Lesions were treated twice weekly with the same dose on both sides for a total of 24 sessions. The evaluation was done by two independent physicians blinded to the treatment on direct light and ultraviolet light photos. RESULTS: Twenty patients were included: 17 completed the study and 104 lesions were treated. The two treatments showed similar results in terms of efficacy for a repigmentation of at least 50% (P = 0.006). The lamp induced more erythema than the laser. CONCLUSIONS: The 308-nm excimer lamp and laser showed a similar efficacy in treating vitiligo. For the same fluence, the lamp induced more erythema suggesting photobiological differences between the two devices.
Subject(s)
Lasers, Excimer/therapeutic use , Low-Level Light Therapy/methods , Ultraviolet Therapy/methods , Vitiligo/radiotherapy , Adult , Algorithms , Dose-Response Relationship, Radiation , Female , Humans , Male , Middle Aged , Prospective Studies , Single-Blind Method , Treatment Outcome , Vitiligo/pathology , Young AdultABSTRACT
BACKGROUND: Hand-foot syndrome (HFS) is a dose-dependent cutaneous side effect of cytostatic chemotherapy. It has also been described under the names of acral erythema and palmoplantar erythrodysesthesia. We report a case of HFS during treatment of acute lymphoblastic leukemia with 6-mercaptopurine (6-MP) (Purinethol) in a four-year-old child. PATIENTS AND METHODS: A four-year-old boy treated for acute lymphoblastic leukemia developed dry and painful palmar and plantar erythema with fissures. The rash began three weeks after up-titration of 6-MP. There was no past history of cutaneous disease and no other potential trigger factors. The rash ceased after 6-MP withdrawal. DISCUSSION: To our knowledge, this is the first case of HFS due to 6-MP therapy in a child. 6-MP is a major reference drug for the management of acute lymphoblastic leukemia. Numerous cytostatic drugs have been involved in such eruptions.